stockrow
Friday 6 November 2026
Export APRE’s income statement to Excel — free account
Aprea Therapeutics, Inc.
APRE Healthcare Biotechnology
Aprea Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $285,800.00, down 81.0% from fiscal 2024.
- Revenue
- −98.4%
- EPS
- +80.9%
- Free cash flow
- −5.22%
Quarter to September 2026, against a year earlier
0.52
0.02
+4.00%
Follow APRE
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | — | — | — |
P/S ratio |
19.45 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(1.88) | — | — | — | |
P/B ratio |
0.45 | — | — | — | |
Price to Tangible BV |
0.45 | — | — | — | |
EV/Sales |
(31.65) | — | — | — | |
EV/EBITDA |
0.68 | — | — | — | |
EV/Operating CF |
0.70 | — | — | — | |
EV/FCF |
0.70 | — | — | — | |
Quick Ratio |
5.28 | 8.77 | 13.33 | 9.52 | |
Current Ratio |
5.63 | 8.92 | 13.55 | 9.67 | |
Net Debt/EBITDA |
5.53 | 13.57 | 10.24 | 7.32 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.21 | 0.84 | 0.91 | 0.77 | |
Capex/Depreciation |
0.00 | 0.00 | (2.66) | 0.00 | |
Research and Development Expense of Revenue |
30,569.70% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
49,624.24% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
3,303.03% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
2.17 | — | — | — | |
Graham Number |
0.00 | — | — | — | |
Earnings Yield |
(232.94%) | — | — | — | |
Free Cash Flow Yield |
(232.27%) | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.45) | (0.19) | (0.06) | (0.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.45) | (0.19) | (0.06) | (0.07) | |
Cash per Share |
2.23 | 3.16 | 0.77 | 0.71 | |
Shareholders Equity per Share |
1.90 | 2.83 | 0.72 | 0.64 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.90 | 2.83 | 0.72 | 0.64 | |
Free Cash Flow |
(2.96) | (2.76) | (3.29) | (3.73) | |
Working Capital |
12.80 | 41.95 | 38.82 | 34.46 | |
Capital Expenditures |
— | — | (0.02) | 0.00 | |
Net Current Asset Value |
12.07 | 41.22 | 38.09 | 33.73 | |
EV/EBIT |
0.68 | — | — | — | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Payables |
1.03 | 2.11 | 1.07 | 0.95 | |
Average Assets |
19.96 | 33.92 | 29.80 | 26.57 | |
Average Common Equity |
15.87 | 28.57 | 25.94 | 22.51 |
Columns are period end dates · fundamentals updated 6 Nov 2026